Showing 5101-5110 of 5554 results for "".
- UCB: Investigational Bimekizumab Helps Psoriatic Arthritis in Phase 1Bhttps://practicaldermatology.com/news/ucb-investigational-bimekizumab-helps-psoriatic-arthritis-in-phase-1b/2458534/Bimekizumab, in development by UCB, has shown promise for the treatment of psoriatic arthritis (PsA) in Phase 1B studies. For the study, a total of 52 PsA patients inadequately controlled with at least one disease-modifying anti-rheumatic drug (DMARD) and/or one biologic were randomized to
- Restylane Turns 20, Galderma Launches New Syringehttps://practicaldermatology.com/news/restylane-turns-20-galderma-launches-new-syringe/2458533/Happy 20th Restylane®! Galderma is celebrating the 20th anniversary of the Restylane line of products. The line includes Restylane®, Restylane-L®, Restylane® Lyft with Lidocaine and Restylane® Si
- New Psoriasis Drug Taltz Shows Benefit Through 60 Weekshttps://practicaldermatology.com/news/new-psoriasis-drug-taltz-shows-benefit-through-60-weeks/2458536/Three new studies demonstrate the efficacy and safety of Eli Lilly's Taltz® (ixekizumab) through 60 weeks among patients with moderate-to-severe plaque psoriasis. The findings appear in the
- Kate Bosworth Partners with Allergan for ACZONE® Gel, 7.5% Launchhttps://practicaldermatology.com/news/kate-bosworth-partners-with-allergan-for-aczone-gel-75-launch/2458540/Actress, producer and model Kate Bosworth is the new face of Allergan plc’s ACZONE® (dapsone) Gel, 7.5%. ACZONE® Gel, 7.5% is a once-a-day prescription topical treatment for acne in patients 12 years of age and older. It was approved
- Pfizer/Anacor Merger To Fuel Already Robust AD Pipelinehttps://practicaldermatology.com/news/pfizeranacor-merger-fuels-already-robust-ad-pipeline/2458542/For years, there were few, if any, promising new treatments for atopic dermatitis (AD), but today the pipeline is robust, and a Pfizer-Anacor merger may help both of the companies’ pipeline candidates gain market share,
- Dermira's DRM04 Shows Promise for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-drm04-shows-promise-for-primary-axillary-hyperhidrosis/2458543/Dermira’s DRM04 may help put the brakes on primary axillary hyperhidrosis, according to topline results from two Phase 3 trials. Based on the results of these trials, Dermira plans to submit a New Drug Application to the US Food and Drug Administ
- Galderma Introduces New Mirvaso Pump Dispenser to Treat Persistent Facial Redness of Rosaceahttps://practicaldermatology.com/news/galderma-introduces-new-mirvaso-pump-dispenser-to-treat-persistent-facial-redness-of-rosacea/2458549/Galderma Laboratories, L.P. launched a new pump dispenser design for Mirvaso (brimonidine) Topical Gel, 0.33% for the treatment of the persistent facial redness associated with rosacea. The Mirvaso Gel Pump is now available by prescription to patients in pharmacies nationwide. The improved
- FDA Accepts Allergan's NDA Filing for Oxymetazoline HCI Cream 1.0% for Facial Erythemahttps://practicaldermatology.com/news/fda-accepts-allergans-nda-filing-for-oxymetazoline-hci-cream-10/2458553/The FDA accepted Allergan plc's New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults. Allergan expects the Prescription Drug User Fee
- Cynosure Receives FDA Clearance to Market PicoSure Energy Delivery System for Tattoos and Pigmented Lesionshttps://practicaldermatology.com/news/cynosure-receives-fda-clearance-to-market-picosure-energy-delivery-system-for-tattoos-and-pigmented-lesions/2458554/The FDA granted clearance to Cynosure to market a new Laser Delivery System for PicoSure. Together with the FDA cleared 532nm and 755nm wavelengths, Cynosure's new 1064nm Laser Delivery System improves the multi-wavelength laser technology for removing the full color spectrum of tattoo inks i
- GlobalMed Technologies Acquires Omnilux Medicalhttps://practicaldermatology.com/news/globalmed-technologies-acquires-omnilux-medical/2458551/GlobalMed Technologies (GMT) has acquired Omnilux Medical, the gold standard for medical and aesthetic Light Emitting Diode (LED) skincare. The asset acquisition includes three Omnilux Medical Systems, the Omnilux Revive2™, Omnilux Blue™ and Omnilux Plus™,